Indeed, while in the stomach the loss of CLDN18 protein was reported to promote inflammation and tumorigenesis, as described in knockout models [43], de novo expression of CLDN18 in small bowel and colon-rectum of IBD patients seemed to be part of the inflammation-metaplasia-dysplasia-cancer process [44, 45]. Here, CLDN18 is linked to inflammatory bowel disease.